SCHEMBL9890673

SCHEMBL9890673

Cc1ccc(-c2ccc(Cl)cc2)c(CC(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
KMT2A Q03164 1/20 0.52
PTGS2 P35354 4/20 0.51
SUCNR1 Q9BXA5 2/20 0.48
FFAR1 O14842 1/20 0.48
FFAR4 Q5NUL3 1/20 0.48
SRC P12931 1/20 0.46
PTGS1 P23219 2/20 0.44
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ABCB11 O95342 1/20 0.43
PPARG P37231 1/20 0.43
NR1I3 Q14994 1/20 0.43
DHODH Q02127 2/20 0.43
GRM2 Q14416 1/20 0.43
ANO1 Q5XXA6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3741692 0.91 FFAR1 (0.57) PTGDR2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL3745897 0.87 KEAP1 (0.47) PTGDR2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL9890778 0.86 GRM2 (0.48) PTGDR2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL9890663 0.85 PTGS1 (0.59) PTGDR2PTGS2SRCPTGS1MAPT
SCHEMBL9890779 0.84 ALDH1A1 (0.44) PTGDR2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL3736882 0.81 AKR1C3 (0.49) PTGDR2SUCNR1FFAR1FFAR4PPARG
SCHEMBL11889697 0.79 PTGER4 (0.49) PTGS2FFAR1FFAR4SRCPTGS1
SCHEMBL3738386 0.79 FFAR1 (0.54) PTGDR2KDM4ESUCNR1FFAR1FFAR4
SCHEMBL15703738 0.79 PTGDR2 (0.55) PTGDR2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL3740233 0.78 FFAR4 (0.57) PTGDR2FFAR1FFAR4SRCPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885KDM4E 829/4885MEN1 1467/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885KDM4E 829/4885MEN1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.